4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 89 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,296,716 | -61.2% | 101,863 | -45.0% | 0.00% | -62.5% |
Q2 2023 | $3,345,462 | -3.1% | 185,139 | -7.8% | 0.01% | -20.0% |
Q1 2023 | $3,453,179 | +1.0% | 200,883 | +30.5% | 0.01% | -9.1% |
Q4 2022 | $3,419,763 | +2490.7% | 153,974 | +836.1% | 0.01% | – |
Q3 2022 | $132,000 | -58.9% | 16,449 | -64.2% | 0.00% | -100.0% |
Q2 2022 | $321,000 | +35.4% | 45,995 | +193.0% | 0.00% | 0.0% |
Q1 2022 | $237,000 | -84.7% | 15,700 | -77.8% | 0.00% | -66.7% |
Q4 2021 | $1,554,000 | – | 70,847 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
VR Adviser, LLC | 3,000,000 | $38,190,000 | 4.02% |
Casdin Capital, LLC | 1,033,811 | $13,160,414 | 1.46% |
BVF INC/IL | 4,007,413 | $51,014,367 | 1.38% |
Deep Track Capital, LP | 2,778,107 | $35,365,302 | 1.36% |
Opaleye Management Inc. | 308,500 | $3,927,205 | 1.28% |
Eagle Health Investments LP | 437,911 | $5,574,607 | 1.23% |
Novo Holdings A/S | 1,200,000 | $15,276,000 | 1.13% |
RA Capital Management | 4,163,211 | $52,997,676 | 1.04% |
VIKING GLOBAL INVESTORS LP | 4,787,914 | $60,950,145 | 0.25% |
HighVista Strategies LLC | 33,419 | $425,424 | 0.20% |